By musiclover - Thu Jul 28, 5:20 pm

• 0 Comments
• 0 views
• Tweet

Edited bymusiclover

• Also Wrote
• 78 arrested in Occupy march due in NY court Thurs
• The NY Times Paywall Is Destined for Failure
• New York hosts Portland in massive clash
• Pa. DEP head fires back at New York lawmakers
• Boy left in New York back in Florida

Vertex Pharmaceuticals Inc’s (VRTX.O) new hepatitis C drug stormed out of the gate, posting sales of nearly $75 million in its first five weeks on the market, and the company’s shares rose.

Incivek, which is likely to become part of the standard of care for hepatitis C and widely expected to become a multibillion-dollar seller, won U.S. approval in May.

“This is a really, really impressive revenue ramp,” Sanford Bernstein analyst Geoffrey Porges said. “You run this trend forward and you get to $200 million in revenue in the third quarter.”

• 0 Comments
• 0 views
• Tweet